donation
To request Mental Health
Services or to access Mental
Health Crisis Services Call:
1-800-375-4357

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Biden Administration Withdraws Vaccine Mandate for Large EmployersFree N95 Masks Begin Arriving in U.S. PharmaciesEngland to Lift Travel Restrictions for Vaccinated VisitorsMany Marijuana Vendors Aim Advertising at Kids: StudyConservatorships Keep the Homeless in Psychiatric Wards Too Long: StudyCrowded Emergency Rooms Cost Lives: StudyColonoscopy Surprise Bills Should Be Thing of the Past, Experts SayBiden Plans to Send 400 Million N95 Masks to Americans for FreeWhite House Launches Website for Free Home COVID Tests One Day Ahead of SchedulePolitics Clouds Folks' Views on COVID Rules, Global Survey ConfirmsCOVAX Program Has Now Sent 1 Billion COVID Vaccines to Poorer NationsAmid U.S. Blood Shortage, New Pressure to Ease Donor Rules for Gay MenSupreme Court Blocks Biden's Vaccine Mandate for Large EmployersWhite House May Soon Offer 'High-Quality' Masks to AmericansAmericans Should Avoid Travel to Canada: CDCRed Cross Says U.S. Blood Supply at Dangerously Low Level'Secondhand Vaping' May Be Unhealthy — Could Public Bans Be Coming?Many Doctors Uninformed on Rights of Disabled PatientsAmid COVID Test Shortages, Price Gouging Is on the RiseSupreme Court Hears Arguments on Biden's Vaccine Mandate for Big BusinessMore Evidence That State Lotteries Didn't Boost Vaccination RatesWhite House Finalizes Plan to Send Americans Free COVID Rapid TestsMembers of Biden’s Transition Team Call for New COVID PlanDirty City Air Killed More Than 1.8 Million People Globally in 2019Telemedicine as Good as In-Person for Many Health Conditions: ReviewPrison Time Shortens Life Spans for Black Americans, But Not WhitesHeat Waves Bring Health Crises to the HomelessBiden Outlines Measures to Fight Omicron, Pleads With Americans to Get VaccinatedProctor & Gamble Recalls Pantene, Herbal Essences Products Due to BenzeneEarly CDC COVID Tests Were Not Only Contaminated, But Flawed: ReportMany Home Health Care Workers in Poor Health ThemselvesPoor Outcome More Likely When Patient Is Female, Surgeon Is Male: StudyMonths After New Rule, More Than Half of U.S. Hospitals Still Don't Disclose Prices OnlineReport Finds World Ill-Prepared for Next PandemicU.S. to Pump $400 Million Into Vaccination Programs for Other CountriesOver 234,000 Pounds of Ham, Pepperoni Recalled Due to ListeriaCOVID Vaccine, Testing Demand Overwhelming PharmaciesAlmost 13 Million Americans Per Year Skip Meds Due to CostAssistance Dogs Bring Big Boost to Deaf PeopleCDC to Toughen COVID Testing for International TravelersOld Spice, Secret Antiperspirants Recalled Due to BenzeneClinical Trials Are Becoming More Diverse, But There's Still Work To DoRural Hospitals' ERs Just as Effective as Urban Ones: StudyKraft Recalls Powdered Drinks Over Metal, Glass ConcernsVials Found in Lab Contained Vaccine, not Smallpox Virus: CDCAdvances in Care, Impact of COVID Highlights of Latest Cardiologists' MeetingAcross America, Black People Have Worse Health OutcomesVials With Smallpox Labels Found at Vaccine Lab in Pennsylvania: CDCWhite House to Spend Billions to Boost COVID Vaccine SupplyAHA News: Health Class May Influence Heart Risk in South Asians
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries

HealthDay News
by Robert Preidt and Robin Foster
Updated: Nov 16th 2021

new article illustration

TUESDAY, Nov. 16, 2021 (HealthDay News) -- Pfizer Inc. announced Tuesday that it has reached an agreement for its promising COVID-19 antiviral pill to be made and sold cheaply in 95 developing nations.

The countries included in the licensing deal are mostly in Africa and Asia, and they account for more than half of the world's population, the company said in a statement. Pfizer is partnering on the agreement with Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to lifesaving drugs for low- and middle-income countries.

Under the terms of the deal, Pfizer will grant a royalty-free license for the pill to MPP and manufacturers can then take out a sublicense. They will receive Pfizer's formula for the drug, and be able to sell it for use in 95 developing countries after regulators authorize the drug in those places.

"Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people. We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our health care systems and saving lives," Pfizer chairman and CEO Albert Bourla said in the statement. "We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs."

Last month, Merck reached a similar deal for its COVID-19 antiviral pill to be made and sold inexpensively in 105 poorer countries.

"The fact that we now have two manufacturer-anywhere licenses for these two drugs is a big change, and it draws a big contrast with the restrictive licensing so far for vaccines," James Love, head of Knowledge Ecology International, a nonprofit that researches access to medical products, told The New York Times.

"This license is so important because, if authorized or approved, this oral drug is particularly well-suited for low- and middle-income countries and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic," MPP executive director Charles Gore said in the Pfizer statement.

However, both the Pfizer and Merck agreements exclude a number of low- and middle-income nations that have been hit hard by the pandemic, including Brazil, China, Cuba, Iraq, Jamaica, Libya and Russia.

More information

Visit the U.S. Food and Drug Administration for more on COVID vaccines.

SOURCES: Pfizer, Inc., statement, Nov. 16, 2021; The New York Times